61C38CFD-F57F-48D2-9FC7-81776647CF0E
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 1.8068331143232588
- age_years
- 36
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.444
- ANDROGEN_RESPONSE+0.393
- TGF_BETA_SIGNALING+0.385
- MYC_TARGETS_V1+0.362
- OXIDATIVE_PHOSPHORYLATION+0.359
- UV_RESPONSE_UP+0.317
- TNFA_SIGNALING_VIA_NFKB+0.308
- WNT_BETA_CATENIN_SIGNALING+0.308
- UV_RESPONSE_DN+0.306
- MTORC1_SIGNALING+0.289
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.313
- COAGULATION-0.262
- IL6_JAK_STAT3_SIGNALING-0.256
- ALLOGRAFT_REJECTION-0.239
- INTERFERON_GAMMA_RESPONSE-0.221
- KRAS_SIGNALING_DN-0.149
- MYOGENESIS-0.136
- ANGIOGENESIS-0.119
- COMPLEMENT-0.053
- IL2_STAT5_SIGNALING-0.046
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9B988854-DC8F-4C67-B8A9-F5D77F0E7497 | — | — | 0.897 |
| 2 | D1BFDB5B-3131-4B5C-8090-B3B91D4450F3 | — | — | 0.850 |
| 3 | B71EF25E-7DDB-42DA-84A5-920A90E85512 | — | — | 0.841 |
| 4 | 2B70C69F-DE54-4C78-B326-5CCEE15916FB | — | — | 0.837 |
| 5 | 09E07A63-5FD2-4E4F-9FD5-2BB204302232 | — | — | 0.831 |
| 6 | CD628EE7-84DE-4D82-840B-73718D006B6F | — | — | 0.814 |
| 7 | A0A24949-483B-4250-B11E-2BCE49F302AC | — | — | 0.811 |
| 8 | 9C30E1C0-1ADE-460B-B53D-297CCA80C071 | — | — | 0.800 |
| 9 | TCGA-CV-7430-01A-11R-2132-07 | — | — | 0.794 |
| 10 | 37A8E941-F86F-449A-86E4-833AC349111F | — | — | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.444 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.393 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.385 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.362 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.359 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.317 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.308 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.308 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.306 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.289 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.288 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.253 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.249 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.249 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.227 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| HYPOXIA | 0.188 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| APOPTOSIS | 0.156 | Idelalisib | — uncovered |